Novo Nordisk recently announced that Wegovy (semaglutide) tablets 25 mg has surpassed 3 million prescriptions in just over 5 months, establishing Wegovy pill as one of the strongest US pharmaceutical launches by volume on record. The 3 million milestone corresponds to 1 prescription filled roughly every 5 seconds, reflecting continued uptake since Wegovy pill became available in January 2026.

Further underscoring its rapid adoption, Wegovy pill reached its initial 1 million prescription milestone just 12 weeks after reaching US pharmacies and online providers (week of 1/5/26 to week of 3/23/26), with an additional 2 million prescriptions accumulated in an even shorter span of just 10 weeks (week of 3/23/26 to week of 6/1/26).

The majority of new prescriptions filled for Wegovy pill (more than 80 percent) are for people new to GLP-1 therapy, indicating the oral formulation is expanding the obesity treatment market, rather than replacing existing therapies.

Jamey Millar, Executive Vice President (EVP)—US Operations, Novo Nordisk, said, "Wegovy offers adults with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events such as death, heart attack, or stroke in adults with obesity with known heart disease–making Wegovy pill truly distinct. With Wegovy pill and Wegovy HD available for weight management, patients and their healthcare providers are making choices that fit their needs, resulting in the clear adoption for both treatments. Novo Nordisk remains determined to continue playing a major part in addressing the global public health challenge of obesity by deeply understanding the needs of those who live with it. That is why we are at ADA 2026–to talk to patients, health care professionals, and investors to present our data but also listen and learn."

This year, more patients starting a new weight management therapy have filled prescriptions for Wegovy than any other available obesity medication. Alongside the 3 million prescription milestone for Wegovy pill, the recently launched Wegovy HD (semaglutide) injection 7.2 mg has demonstrated strong uptake in the early days of availability.

Expanding affordable access to medicines is a priority for Novo Nordisk including the expansion of coverage for those with insurance in the US. Those with commercial insurance coverage can access Wegovy for as little as USD 25 per month through existing savings programs. The recently announced Medicare GLP-1 Bridge builds on these efforts to expand access and will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a USD 50 monthly copay†, beginning July 1, 2026.

In addition, Wegovy is available through a range of access options, including over 70,000 US pharmacies, NovoCare Pharmacy, select telehealth providers, and others.

Novo Nordisk is preparing for the first launches of the Wegovy pill outside the US in the second half of 2026, including the recently announced approval and launch in the United Arab Emirates (UAE).